Thus, our study has identified sulfarotene as a potential therapeutic agent for treating the TRCs of HCC by targeting a novel RARα-SOS2-RAS signal axis, which plays critical roles in tumorigenicity of TRCs and mediation of the therapeutic effects of sulfarotene. The gene discussed is SOS2; the disease is hepatocellular carcinoma.